Tags : AI based


Boehringer Ingelheim Collaborates with Insilico on AI-Based Drug Discovery

Shots: The collaboration will utilize Insilico’s generative ML technology and Pandomics discovery platform to identify potential therapeutic targets implicated in multiple diseases Insilico’s Pandomics platform will foster Boehringer’s capabilities to explore and identify drug targets and improves the drug discovery process contributing to human health In Jan 2020, Insilico Medicine allied with skincare firm Beiersdorf […]Read More


Bayer Signs a Three Year Multi Target AI-based Agreement with

Shots: Exscientia to get up to $266.2M including upfront, research payments and clinical milestones plus royalties on sales. Bayer to get rights for the developed therapies under collaboration   The partners will focus on early research projects combining Exscientia’s AI drug discovery platform and drug design know-how with Bayer’s data and drug discovery capabilities for […]Read More


Roche Signs an AI-Based Research Agreement with Sensyne Health

Shots: Roche and Sensyne Health collaborate to apply AI technology for clinical trial designs and will further strengthen Roche’s approach in data and technology-driven personalized healthcare The collaboration will focus on identifying patient’s population in one disease and further assessing and collating anonymized patient data with anonymized EHR data for supporting clinical trial planning In […]Read More